Vasoactive intestinal peptide receptor 1 is downregulated during expansion of antigen-specific CD8 T cells following primary and secondary Listeria monocytogenes infections

Journal of Neuroimmunology

Volumn 234, Issue 1-2, 2011, Pages 40-48

  Vomhof DeKrey, Emilie E ^a   Haring, Jodie S ^a   Dorsam, Glenn P ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

CD8 T cell; Memory T cells; Neuropeptide; Neuropeptide receptor; VIP; VPAC1

Indexed keywords

MESSENGER RNA; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; GENE SILENCING; IMMUNE RESPONSE; LISTERIOSIS; MEMORY CELL; MOUSE; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; SECONDARY INFECTION;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES; ANTIGENS, CD3; ANTIGENS, THY-1; CD8-POSITIVE T-LYMPHOCYTES; CYCLIC AMP; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; LISTERIOSIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA, MESSENGER; TIME FACTORS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 79955661683     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.02.002     Document Type: Article

References (45)

1. Badovinac V.P., Haring J.S., Harty J.T. Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T cell response to infection. Immunity 2007, 26:827-841.
2. Bellinger D.L., Lorton D., Brouxhon S., Felten S., Felten D.L. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv. Neuroimmunol. 1996, 6:5-27.
3. Bellinger D.L., Lorton D., Horn L., Brouxhon S., Felten S.Y., Felten D.L. Vasoactive intestinal polypeptide (VIP) innervation of rat spleen, thymus, and lymph nodes. Peptides 1997, 18:1139-1149.
4. Bemelmans M.H., Abramowicz D., Gouma D.J., Goldman M., Buurman W.A. In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice. Effects of pentoxifylline, methylprednisolone, anti-TNF, and anti-IFN-gamma antibodies. J. Immunol. 1994, 153:499-506.
5. Delgado M., Ganea D. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J. Immunol. 2000, 165:3051-3057.
6. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression. J. Immunol. 2000, 165:114-123.
7. Delgado M., Martinez C., Johnson M.C., Gomariz R.P., Ganea D. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J. Neuroimmunol. 1996, 68:27-38.
8. Delgado M., Martinez C., Leceta J., Gomariz R.P. Vasoactive intestinal peptide in thymus: synthesis, receptors and biological actions. Neuroimmunomodulation 1999, 6:97-107.
9. Delgado M., Munoz-Elias E.J., Gomariz R.P., Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J. Neuroimmunol. 1999, 96:167-181.
10. Delgado M., Leceta J., Sun W., Gomariz R.P., Ganea D. VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression. Ann. NY Acad. Sci. 2000, 921:68-78.
11. Delgado M., Pozo D., Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 2004, 56:249-290.
12. Dickson L., Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol. Ther. 2009, 121:294-316.
13. Dorsam S.T., Vomhof-Dekrey E., Hermann R.J., Haring J.S., Van der Steen T., Wilkerson E., Boskovic G., Denvir J., Dementieva Y., Primerano D., Dorsam G.P. Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells. Mol. Immunol. 2010, 47(6):1181-1194.
14. D'Souza W.N., Chang C.F., Fischer A.M., Li M., Hedrick S.M. The Erk2 MAPK regulates CD8 T cell proliferation and survival. J. Immunol. 2008, 181:7617-7629.
15. Haring J.S., Corbin G.A., Harty J.T. Dynamic regulation of IFN-gamma signaling in antigen-specific CD8+ T cells responding to infection. J. Immunol. 2005, 174:6791-6802.
16. Hirsch R., Gress R.E., Pluznik D.H., Eckhaus M., Bluestone J.A. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J. Immunol. 1989, 142:737-743.
17. Hogquist K.A., Jameson S.C., Heath W.R., Howard J.L., Bevan M.J., Carbone F.R. T cell receptor antagonist peptides induce positive selection. Cell 1994, 76:17-27.
18. Jabbari A., Harty J.T. Secondary memory CD8+ T cells are more protective but slower to acquire a central-memory phenotype. J. Exp. Med. 2006, 203:919-932.
19. Jameson S.C., Masopust D. Diversity in T cell memory: an embarrassment of riches. Immunity 2009, 31:859-871.
20. Jiang X., Wang H.Y., Yu J., Ganea D. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes. Ann. NY Acad. Sci. 1998, 865:397-407.
21. Johnson M.C., McCormack R.J., Delgado M., Martinez C., Ganea D. Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. J. Neuroimmunol. 1996, 68:109-119.
22. Johnston J.A., Taub D.D., Lloyd A.R., Conlon K., Oppenheim J.J., Kevlin D.J. Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide. J. Immunol. 1994, 153:1762-1768.
23. Lara-Marquez M.L., O'Dorisio M.S., Karacay B. Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes. Ann. NY Acad. Sci. 2000, 921:45-54.
24. Lara-Marquez M., O'Dorisio M., O'Dorisio T., Shah M., Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Immunol. 2001, 166:2522-2530.
25. Lefrancois L. Development, trafficking, and function of memory T-cell subsets. Immunol. Rev. 2006, 211:93-103.
26. Metwali A., Elliott D., Blum A.M., Li J., Sandor M., Lynch R., Noben-Trauth N., Weinstock J.V. The granulomatous response in murine Schistosomiasis mansoni does not switch to Th1 in IL-4-deficient C57BL/6 mice. J. Immunol. 1996, 157:4546-4553.
27. Metwali A., Blum A.M., Li J., Elliott D.E., Weinstock J.V. IL-4 regulates VIP receptor subtype 2 mRNA (VPAC2) expression in T cells in murine schistosomiasis. FASEB J. 2000, 14:948-954.
28. Ottaway C.A. In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells. J. Exp. Med. 1984, 160:1054-1069.
29. Ottaway C.A., Greenberg G.R. Interaction of vasoactive intestinal peptide with mouse lymphocytes: specific binding and the modulation of mitogen responses. J. Immunol. 1984, 132:417-423.
30. Pincus D.W., DiCicco-Bloom E.M., Black I.B. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 1990, 343:564-567.
31. Pope C., Kim S.K., Marzo A., Masopust D., Williams K., Jiang J., Shen H., Lefrancois L. Organ-specific regulation of the CD8 T cell response to Listeria monocytogenes infection. J. Immunol. 2001, 166:3402-3409.
32. Pozo D., Anderson P., Gonzalez-Rey E. Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J. Immunol. 2009, 183:4346-4359.
33. Qian B.F., Hammarstrom M.L., Danielsson A. Differential expression of vasoactive intestinal polypeptide receptor 1 and 2 mRNA in murine intestinal T lymphocyte subtypes. J. Neuroendocrinol. 2001, 13:818-825.
34. Rai D., Pham N.L., Harty J.T., Badovinac V.P. Tracking the total CD8 T cell response to infection reveals substantial discordance in magnitude and kinetics between inbred and outbred hosts. J. Immunol. 2009, 183:7672-7681.
35. Said S.I. Candidate hormones of the gut. V. Vasoactive intestinal peptide (VIP). Gastroenterology 1974, 67:735-737.
36. Said S.I., Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970, 169:1217-1218.
37. Sharma V., Delgado M., Ganea D. Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J. Immunol. 2006, 176:97-110.
38. Smalley S.G., Barrow P.A., Foster N. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin. Exp. Immunol. 2009, 157:225-234.
39. Sreedharan S.P., Huang J.X., Cheung M.C., Goetzl E.J. Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc. Natl Acad. Sci. USA 1995, 92:2939-2943.
40. Vassiliou E., Jiang X., Delgado M., Ganea D. TH2 lymphocytes secrete functional VIP upon antigen stimulation. Arch. Physiol. Biochem. 2001, 109:365-368.
41. Voice J.K., Dorsam G., Lee H., Kong Y., Goetzl E.J. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J. 2001, 15:2489-2496.
42. Voice J., Donnelly S., Dorsam G., Dolganov G., Paul S., Goetzl E.J. c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J. Immunol. 2004, 172:7289-7296.
43. Vomhof-DeKrey E.E., Dorsam G.P. Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells. Brain Behav. Immun. 2008, 22:1024-1031.
44. Vomhof-DeKrey E.E., Hermann R.J., Palmer M.F., Benton K.D., Sandy A.R., Dorsam S.T., Dorsam G.P. TCR signaling and environment affect vasoactive intestinal peptide receptor-1 (VPAC-1) expression in primary mouse CD4 T cells. Brain Behav. Immun. 2008, 22:1032-1040.
45. Xin Z., Tang H., Ganea D. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production in murine thymocytes activated via the TCR/CD3 complex. J. Neuroimmunol. 1994, 54:59-68.